Ezetimibe - horizon scanning review

Record ID 32002000853
Authors' objectives:

To summarise the current research evidence on ezetimibe for hyperlipidaemia.

Authors' recommendations: - Clinical impact: The long-term gains of a reduction in the risk of future CV events following any reduction in individual and population cardiac risk factors including lipid profiles, is potentially highly significant. - Service impact: There will be no additional impact (over and above the impact of the CHD NSF) on health services with the introduction of ezetimibe. - Patient issues: Ezetimibe will represent another option for patients who are unable to tolerate statins or who do not achieve their target lipid levels. - Financial and overall NHS impact: This is difficult to estimate at this time, but may be significant because of the large eligible patient group.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
URL for published report: http://www.hsric.nihr.ac.uk/search
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Cholesterol
  • Coronary Disease
  • Hyperlipidemias
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: National Horizon Scanning Centre
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.